ABOUT US

Joan

Dr. Joan Perelló

CEO and co-founder

Alex-Gold

Alexander M. Gold M.D.

CMO

Cris-Calsada

Cris Calsada

CFO

Carol-Salcedo

Dr. Carolina Salcedo

CSO

Antonio-Jimenez

Mr. Antonio Jiménez

General Counsel & VP Operations

Rekha-Garg

Dr. Rekha Garg

SVP Development, Regulatory & Safety

Claire-Padgett

Dr. Claire Padgett

SVP, Development Operations

Marco-Moreno

Dr. Marco Antonio Moreno

VP Manufacturing

Susie-Lundeen

Ms. Susan Lundeen

Head of People

Latest News

04 03 2019

Data from SNF472 Phase 1b Clinical Trial published in British Journal of Clinical Pharmacology

21 11 2018

Sanifit highlights publication of “50 Key Questions on Calciphylaxis”

23 10 2018

Data from first in-human clinical trial of SNF472 in haemodialysis patients published in British Journal of Clinical Pharmacology

06 08 2018

Sanifit announces completion of enrollment in CaLIPSO – its Phase 2b Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis

Board of directors

Russell

Russell G. Greig

Chairman of the Board

Joan

Joan Perelló

Managing Director

jose-antonio-mesa

José Antonio Mesa

Board Member

joel-jean-mairet

Joël Jean-Mairet

Board Member

casper-breun

Casper Breum

Board Member

Geert-Jan-Mulder

Geert-Jan Mulder

Board Member

edwin-de-graft

Edwin de Graaf

Board Member

Sofia Ioannidou

Sofia Ioannidou

Board Member

Keith-Leonard

Keith R. Leonard

Board Member

Anne-Sissel-BAXTER

Anne E. Sissel

Board Observer

Marisa-Guitart

Marisa Guitart

Board Advisor

Our Investors

Sanifit is backed by a strong syndicate of international investors. These investors include Venture Capital Funds, Corporate Venture Funds and several private investors (Invenzia, Toni and Guillem Ballester, Nefrona Foundation, Somtobir and several ex Phadia and ex Pharmacia employees and directors) represented by MGA.

To date, the company has raised over €40 million equity. The Company ’s main investors include:

La Caixa Capital Risc

MGA Business Consulting

Health Equity

Ysios Capital

Lundbeckfond Ventures

Forbion

Gilde Healthcare

Edmond de Rothschild Investment Partners

Baxter Ventures